Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

November 20, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

TCTMD’s Top 10 Most Popular Stories for December 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

December 29, 2021

TCTMD’s Top 10 Most Popular Stories for March 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

April 02, 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

TCTMD’s Top 10 Most Popular Stories for January 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

January 31, 2019

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.